Building on its extensive experience in stem cell transplantation, the program has served as a springboard for developing a comprehensive immune effector cell therapy program. CAR-T therapy, an approach that reengineers a patient’s immune cells to be able to recognize and attack cancer cells, is a new and important building block for the immune effector cell therapy program.
For the past 30 years, adoptive cellular therapy with immune effector cells including a variety of lymphocytes, have been developed at research centers around the world, including Baylor University Medical Center, part of Baylor Scott & White Health. Chimeric Antigen Receptor (CAR) T cells have emerged from the lab as FDA-approved treatments for a variety of cancers. This includes some gene-modified T cells and natural (NK) cells. The future for effector cell therapy is bright, as it becomes the treatment of choice for many cancer patients. Baylor Dallas will continue to play a leading role in these pioneering efforts. Read more about CAR-T Cell Therapy on our medical professional website.